Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys

被引:104
作者
Seaman, MS
Xu, L
Beaudry, K
Martin, KL
Beddall, MH
Miura, A
Sambor, A
Chakrabarti, BK
Huang, Y
Bailer, R
Koup, RA
Mascola, JR
Nabel, GJ
Letvin, NL
机构
[1] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02215 USA
[2] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1128/JVI.79.5.2956-2963.2005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The development of a human immunodeficiency virus type 1 (HIV-1) vaccine that elicits potent cellular and humoral immune responses recognizing divergent strains of HIV-1 will be critical for combating the global AIDS epidemic. The present studies were initiated to examine the magnitude and breadth of envelope (Env)specific T-lymphocyte and antibody responses generated by vaccines containing either a single or multiple genetically distant HIV-1 Env immunogens. Rhesus monkeys were immunized with DNA prime-recombinant adenovirus boost vaccines encoding a Gag-Pol-Nef polyprotein in combination with either a single Env or a mixture of clade-A, clade-B, and clade-C Envs. Monkeys receiving the multiclade Env immunization developed robust immune responses to all vaccine antigens and, importantly, a greater breadth of Env recognition than monkeys immunized with vaccines including a single Env immunogen. All groups of vaccinated monkeys demonstrated equivalent immune protection following challenge with the pathogenic simian-human immunodeficiency virus 89.6P. These data suggest that a multicomponent vaccine encoding Env proteins from multiple clades of HIV-1 can generate broad Env-specific T-lymphocyte and antibody responses without antigenic interference. This study demonstrates that it is possible to generate protective immune responses by vaccination with genetically diverse isolates of HIV-1.
引用
收藏
页码:2956 / 2963
页数:8
相关论文
共 26 条
  • [1] Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa
    Bures, R
    Morris, L
    Williamson, C
    Ramjee, G
    Deers, M
    Fiscus, SA
    Abdool Karim, SS
    Montefiori, DC
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (05) : 2233 - 2244
  • [2] Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1
    Bures, R
    Gaitan, A
    Zhu, TF
    Graziosi, C
    McGrath, KM
    Tartaglia, J
    Caudrelier, P
    EL Habib, R
    Klein, M
    Lazzarin, A
    Stablein, DM
    Deers, M
    Corey, L
    Greenberg, ML
    Schwartz, DH
    Montefiori, DC
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (18) : 2019 - 2035
  • [3] Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development
    Cao, HY
    Kanki, P
    Sankale, JL
    DiengSarr, A
    Mazzara, GP
    Kalams, SA
    Korber, B
    Mboup, S
    Walker, BD
    [J]. JOURNAL OF VIROLOGY, 1997, 71 (11) : 8615 - 8623
  • [4] Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization
    Chakrabarti, BK
    Kong, W
    Wu, B
    Yang, ZY
    Friborg, J
    Ling, X
    King, SR
    Montefiori, DC
    Nabel, GJ
    [J]. JOURNAL OF VIROLOGY, 2002, 76 (11) : 5357 - 5368
  • [5] CHAKRABARTI BK, UNPUB EXPANDED BREAD
  • [6] Clonally diverse CTL response to a dominant viral epitope recognizes potential epitope variants
    Charini, WA
    Kuroda, MJ
    Schmitz, JE
    Beaudry, KR
    Lin, WY
    Lifton, MA
    Krivulka, GR
    Necker, A
    Letvin, NL
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 167 (09) : 4996 - 5003
  • [7] Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines
    Fattom, A
    Cho, YH
    Chu, CY
    Fuller, S
    Fries, L
    Naso, R
    [J]. VACCINE, 1999, 17 (02) : 126 - 133
  • [8] Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines
    Ferrari, G
    Kostyu, DD
    Cox, J
    Dawson, DV
    Flores, J
    Weinhold, KJ
    Osmanov, S
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (14) : 1433 - 1443
  • [9] AIDS - Diversity considerations in HIV-1 vaccine selection
    Gaschen, B
    Taylor, J
    Yusim, K
    Foley, B
    Gao, F
    Lang, D
    Novitsky, V
    Haynes, B
    Hahn, BH
    Bhattacharya, T
    Korber, B
    [J]. SCIENCE, 2002, 296 (5577) : 2354 - 2360
  • [10] Clinical trials of HIV vaccines
    Graham, BS
    [J]. ANNUAL REVIEW OF MEDICINE, 2002, 53 : 207 - 221